I am currently an assistant professor of Biology at Limestone University in South Carolina teaching

undergraduate Biology curriculum. My other appointments are more research-based and include Research Professor in the Pharmaceutical Science Department at Northeastern University in Boston to continue my cannabinoid research, and as a Research Scientist at The University of Connecticut in Storrs CT, where I received my PhD in 2008 working in the department of Pharmaceutical Sciences/Toxicology and Neuroscience Program.

I previously taught from 2011-2016 as affiliated faculty in the Neuroscience Graduate Program at the University of Hartford after completing postdoctoral fellowships at the Harvard Medical School in Boston studying non-human primate age-related brain pathology, and at UConn to do work focusing on whether gene expression changes were induced with drug treatment conducted for my thesis. I feel that my qualifications are an excellent match for the opportunity in your program. I am free to discuss the particulars to determine if this is a good fit for both of us. David Butler, Ph.D.

Assistant Professor of Biology

Department of Science & Mathematics

Limestone University

1115 College Dr., Gaffney, SC 29340-3799

office: HAM122 phone 864-***-****, mobile 443-***-**** ad29kf@r.postjobfree.com

655 Talcottville Rd unit 163

Vernon CT 06066

ad29kf@r.postjobfree.com ad29kf@r.postjobfree.com

Education

Year Degree Institution

2008 PhD, Pharmacology/Toxicology University of Connecticut Thesis: Butler D. Selective enhancement of lysosomal responses clears Alzheimer’s disease protein deposits and concomitantly reduces synaptic and behavioral deficits. Storrs (CT): University of Connecticut; 2008, registration number TX 6-658-442, Ben A Bahr, Advisor

2003 MS, Neuroscience University of Hartford, CT

Thesis: Butler D. Effects of caloric restriction and ketogenic diets on leptin and insulin levels. Jacob P Harney, Advisor

2001 BA, Psychology Salisbury University, MD

Senior Thesis: Attitudes That Influence Recreational Drug Use. (abstract) Eastern Psychology meeting, 2001. Wash DC. Alfred A. Witkofsky, Advisor

2001-2003 research assistant University of Hartford 2003-2008 graduate assistant University of Connecticut 2008-2009 postdoctoral fellow University of Connecticut 2009-2010 postdoctoral fellow Harvard Medical School Project: Age-related Alzheimer-type pathogenesis in brains of non-human primate green vervet. Cynthia A. Lemere, Advisor

Research Interests

• Biomedical research, Alzheimer’s disease, and neurodegenerative diseases

• Neural consequences of altered metabolism

• Age-related changes in the brain

• Cognitive and behavioral disruptions and protective strategies

• Neuropharmacology, drug discovery

Memberships

1999 Psi Chi Honor Society

2001-current Society for Neuroscience

2003-2004 Center for Drug Discovery University of Connecticut 2005-present Center for Drug Discovery Northeastern University 2005-2009 Genetics, genomics, bioinformatics initiative University of Connecticut 2007- American Society for Pharmacology & Experimental Therapeutics (ASPET) 2010-current member, Council on Undergraduate Research Washington, DC Teaching and Appointments

2023-24 Assistant Professor of Biology Limestone University 2017-24 Research Professor, Center for Drug Discovery Northeastern University 2016-current Research Scientist, School of Pharmacy University of Connecticut 2011-2016 Part time adjunct faculty, Neuroscience Program University of Hartford 2011-16 Neurophysiology Lab coordinator and part-time instructor University of Hartford, Neuroscience graduate program (BIO538). Vivarium Supervisor

2012-13 Summer Health and Science Camp (Hartford High School) Instructor, Neuroscience. 2013 -19 Advanced Pharmacology PHAR5471 (CNS receptor theory) University of Connecticut Pharmaceutical Sciences graduate program, Storrs, CT, Lecturer

2000-2001 invited lecturer undergraduate classes, disability-related issues and traumatic brain injury 2003-07 teaching assistant Biostatistics and evaluation skills (PHRX200/5000/3007), University of Connecticut, prepared visual aids, available to student questions, and lectured when professor out of town. 2009 guest lecturer brain pathogenesis in Alzheimer’s disease Trinity College, Hartford, CT Mentoring Experience

2011-16 committee member, students’ master’s research University of Hartford 2009 co-mentored summer students in Bahr lab University of Connecticut 2009-10 co-supervised summer undergraduate researchers Harvard Medical School 2005-09 co-supervised undergraduate researchers, Bahr lab University of Connecticut SUPERVISED UNDERGRADS IN RESEARCH LAB: UConn

med sch Jeanette Yeh (Molecular & Cell Biology) 2003-05 T. Perrin Sanjida Karim (Mol. Cell Biology, Healthcare Economics) 2003-06 med sch Lara Batey (Mol. Cell Biology) (Pfizer fellowship) 2004-06 PharmD Kelly X. Zhang (Pharm.D.) (Internship; Beth Israel residency) 2003-07 PharmD Malgorzata Michalowska (Pharm.D.) (internship) 2005-07 PharmD Atula Tarpada (Pharm.D.) 2005-07

Rutgers Kehinde Ajayi (Dept. of Chemistry) (Undergrad Research Fellow) 2003-04 Roee Ramot (Biomedical Engineering) 2004-05

biotech Douglas Chin (Dept. of Chemistry) 2004-05

Jihyun Jeong (Mol. Cell Biology) 2005

grad sch Jeannie Hwang (Mol. Cell Biology) 2005-07 Olga Chrzastek (Mol. Cell Biology) (Honors student) 2005-06 Amber Au (Pharmacy) (Honors student) 2005-06

Robert Kwon (Mol. Cell Biology) 2005-09

Dennis So (Pharmacy) 2005-07

Med sch Victoria Baczek (Pharmacy) (Honors student) 2006 Hina Tarpada (Mol. Cell Biology) (SIT Fellow) 2006-08 Arthur Colon (Physiology and Neurobiology) 2007-09 Fulbright Ana Charalambides (Chemistry) 2007-11

Brittni Peterson (Summer Intern Program) 2008

Jiehyun Lee (Pharmacy) 2008

Matt Varga (Mol. Cell Biology) 2008-10

Supervised Graduate Students University Hartford into doctorate programs. U Maine Cara Sullivan Neuroscience MS 2012-3

Kent State John Grizzanti Neuroscience MS 2012-3

Utah Daniel Burns Neuroscience MS 2012-3

2008 Co-mentor for the NSF-funded Research Experience for Undergraduates (REU) Program 2001-2002 mentored undergraduate researcher, genotyping of mouse colony, University of Hartford Editorial Experience

2008 Food and Chemical Toxicology ad hoc reviewer

2009 English editing MS# EJP-30806R1

2011-14 Journal of Proteome Research ad hoc reviewer 2015-18 J. Neuropsychopharmacology ad hoc reviewer 2017 Journal of Nature and Science ad hoc reviewer 1018-20 Journal Pharmacology and Experimental Therapeutics ad hoc reviewer 2021 Scientific Reports ad hoc reviewer

2021 Neural Regeneration Research ad hoc reviewer

Honors

1991 PSI CHI Honor Society

2005 Scholarship from Students with Disabilities Program, University of Connecticut 2007 Neurosciences Fellowship University of Connecticut 2008 Edward Victor Gant Scholarship, Life Achievements University of Connecticut 2009 Outstanding Young Investigator Award, Alzheimer’s Drug Discovery Foundation Research Support

2022 R21 NIH Testing the efficacy and potential tolerance of FAAH inhibitors in mice for future therapeutics(in revision, 1R21NS133833-01).

2015 “Effects on Brain Health in Mice with Extreme Glucose and Insulin Manipulation”. 1R15NS087609-1A1

(withdrawn).

2018 (NIH) “Enhancing the Endocannabinoid System in a mouse model of AD and Excitotoxicity with FAAH inhibitors”.

2019 Bright Focus Foundation “Endocannabinoid enhancement in mouse models of Alzheimer’s Disease” 2019 NIH Determining Controlled Enhancement of the Endocannabinoid System for Models of Neurodegeneration

2011-2016 University of Hartford Neuroscience graduate research fund 2007 University of Connecticut Neuroscience Fellowship 2005 University of Connecticut, Research Scholarship Center for Students with Disabilities 2004 National Institute of Drug Abuse, 3-year study Opportunities for Special Populations Bibliography *denotes mentored undergraduate researcher, ** corresponding author McCarthy K, Harney JP, **Butler D (20xx) Metabolic, Behavioral and Accumulation Consequences with Long- term administration of a Ketogenic diet in Weanling Male Rats (In revision, Plos1, 202x).

*Hwang J, *Estick CM, Ikonne US, Butler D, Pait MC, Elliott LH, Hafner-Ruiz S, Smith K, Rentschler KM, Mundell C, Almeida MF, Stumbling Bear N, Locklear JP, Abumohsen Y, Farizatto KLG, and Bahr BA. The role of lysosomes in a therapeutic approach for synaptic and memory restoration in transgenic models of Alzheimer's disease and Parkinson's disease and in models of mild cognitive impairment. (Int. J. Mol. Sci. 2019, 20, 4432). doi: 10.3390/ijms20184432.

Romine H, Rentschler KM, Smith K, Edwards A, Colvin C, Farizatto K, Pait MC, Butler D, and Bahr BA (2017) Potential Alzheimer’s disease therapeutics among weak cysteine protease inhibitors exhibit mechanistic differences regarding extent of cathepsin B up-regulation and ability to block calpain. (October; 13: 38–59. doi:10.19044/esj. 2017.c1p5).

Harney JP, Gudsnuk K, Patel A, Vellipuram AR, Bandaru S, Butler D (2016) Endocrine and Reproductive Effects of Ketogenic Diets. Ketogenic Diet and Metabolic Therapies Oxford University Press, editor, Masino. Chapter 25 pp 227- 240.

Scichilone JM, Yarraguntla K, *Charalambides A, Harney JP, **Butler D (2016) Environmental Enrichment Mitigates Detrimental Cognitive Effects of Ketogenic Diet in Weanling Rats. J Mol Neurosci 60:1-9. Bahr BA, Wisniewski ML, and Butler D (2012) Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases. Rejuvenation Res 15:189-197. Butler D, *Hwang J, *Estick C, Nishiyama A, Kumar SS, Baveghems C, Young-Oxendine HB, Wisniewski ML,

*Charalambides A, and Bahr BA (2011) Protective effects of positive lysosomal modulation in Alzheimer’s disease transgenic mouse models. PLoS One 6: e20501 (pp 1-16). Naidoo V, Nikas SP, Karanian DA, *Hwang J, Zhao J, Wood JT, Alapafuja SO, Vadivel SK, Butler D, Makriyannis A, and Bahr BA (2011) A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity. Mol Neuroscience 43:493-502.

*Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, and Bahr BA (2010) Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sciences (special issue: Emerging Technologies in Drug Development) 86:615-623. Butler D, Bendiske J, Michaelis ML, Karanian DA, and Bahr BA (2007) Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol 562:20-27. Butler D and Bahr BA (2006) Oxidative stress and lysosomes: CNS-related consequences and implications for lysosomal enhancement strategies and induction of autophagy. Antioxid Redox Signal 8:185-196. Butler D, Nixon RA, and Bahr BA (2006) Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy 2:234-237.

*Batey L, *Chin DJ, *Karim S, Karanian DA, Butler D, and Bahr BA (2005) Lysosomal modulation and autophagic induction: Compensatory processes in response to protein deposition pathology. In Fisher A, Hanin I, Memo M, Stocchi F (eds): New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2005. Bologna, Italy: Medimond S.r.l., pp 55-58.

Butler D, Brown QB, *Chin DJ, *Batey L, *Karim S, Mutneja MS, Karanian DA, and Bahr BA (2005) Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. Rejuvenation Res 8:227-2 Abstracts Presented at Meetings:

Dobbos R, Gray E, Harney JP, Makriyannis A, Butler D (2017, 18). Fatty Acid Amide Hydrolase inhibition increases CB1-Receptor Activity in brains of hybrid B6129SF2/J mice: controls for a Mouse model of Alzheimer’s disease. CPDA, Boston

Frost JL, Luo EM, Butler D, Palmour RM, Ervin FR, Mansfield KG, Westmoreland SV, Saido TC, Demuth HU, Schilling S, Lemere CA. Deposition of A pyroglutamate-3 in brains of mice, monkeys, and humans. Neuroscience 627.23 2009 SFN, Chicago.

Butler D, Estick C, *Batey L, *Hwang J, *Karim S, Barnes SN, Manautou JE, Bahr BA. Modulation of the Lysosomal System Improves Neuronal Integrity and Behavioral Performance in mouse models of Alzheimer’s disease. AHAF and ISAO Workshop 2008, Update in Alzheimer’s Disease Research. Hwang J, Butler D, Ryzhikov S, Colon A, Tarpada H, Tarpada A, Markus EJ, Chrobak JJ, Estick C, Viswanathan K, Nishiyama A, Wright DL, Karanian DA, and Bahr BA. Lysosomal enhancement promotes functional recovery in the APPswe/PS1E9 mouse model of Alzheimer’s disease. Soc. Neurosci. Abstr., 157.12 (2007). Butler D, *Batey L, *Hwang J, *Karim S, *Zhang KX, *Michalowska M, Barnes SN, Manautou JE, Bahr, BA. Lysosomal enhancement promotes functional recovery in the APPSwInd mouse model of Alzheimer’s disease. Soc Neurosci 2007.

Butler D, *Chin DJ, *Batey L, and Bahr BA Compensatory responses in models of protein accumulation events. Soc. Neurosci 2005, Washington D.C.

Butler, D, and Witkofsky AA. Attitudes that influence recreational drug use. Eastern Psychological Association 2001, Washington D.C.

Additional Abstracts

Harney JP, Grizzanti J, Barry M, Burns D, McCarthy K, Butler D. Effects of ketogenic diet on cognition and development of Alzheimer’s disease (AD) in an AD mouse model. Soc. Neurosci. Abstr., 690.18 (2014). Scichilone J, Butler D, Harney JP (2012) Soc. Neurosci. Abstr. Wisniewski ML, Hoover DJ, Hwang J, Viswanathan K, Butler D, Wright D, and Bahr BA. Development of novel lysosomal modulators for treating protein accumulation diseases. 16th Congress of the European Federation of Neurological Societies

(EFNS) (Sweden) A-457-2121 (2012).

Bahr BA, Wisniewski ML, Butler D, Hoover DJ, Viswanathan K, Quizon PMP, Romine H, Anunobi V, and Wright DL. Development of non-peptidyl small molecules for positive lysosomal modulation and protection against protein accumulation disorders. Soc. Neurosci. Abstr. 173.18 (2012).

Young H, Butler D, Estick C, Hwang J, Kumar S, Charalambides A, Howell R, Wisniewski ML, Bahr BA. Lysosomal Modulator Protects in Alzheimer’s Disease Transgenic Mouse Models: Evidence of Enhanced Expression and Trafficking of Cathepsin B. 108th Annual Meeting of the North Carolina Academy of Science (2011). Wisniewski ML, Hoover DJ, Sumskaya Y, Hwang J, Viswanathan K, Butler D, Charalambides A, Wright D, and Bahr BA. Development of non-peptidyl lysosomal modulators. 5th Strategies for Engineered Negligible Senescence (SENS) Conference

(Cambridge, UK). Rejuvenation Res 14: S-43 (2011). Young H, Butler D, Estick C, Hwang J, Kumar S, Kwon R, Cooper J, Wisniewski ML, and Bahr BA. Modulation of a proteolytic system to offset pathogenic protein accumulation events. Gordon Research Conference (Proteolytic Enzymes & Their Inhibitors. Proteolysis: The Most Important And Ubiquitous Post Translational Modification That Regulates Biology, Life And Death). Barga, Italy (2010).

Butler D, Hwang J, Estick C, Nishiyama A, Kumar SS, Baveghems C, and Bahr BA. Lysosomal modulation reduces intracellular and extracellular Aβ accumulations and promotes neuronal integrity in Alzheimer’s disease mouse models. Alzheimer's and Dementia 6 (Alzheimer’s Association Internatl.Conf. on Alzheimer's Disease) (2010). Bahr BA, Butler D, Hwang J, Estick C, Nishiyama A, Kwon R, Colon A, and Charalambides A. Lysosomal modulation ameliorates Alzheimer-type pathology: Evidence of protective cleavage of Aβ42 by modulated cathepsins. FASEB J 23:938.10

(2009).

Peterson B, Kwon R, Hwang J, Colon A, Estick C, Butler D, Karanian DA, Makriyannis A, and Bahr BA. Enhancing neuroprotective endocannabinoid responses and the safety evaluation of FAAH inhibitor AM5206 in rats. MidBrains 2009

(2009).

Bahr BA, Butler D, Hwang J, and Estick C. Potential combination therapies stemming from strategies against LSDs and PADs. Mol. Genet. Metab. 96, S14 (Lysosomal Disease Network Annual World Symposium) (2009). Bahr BA, Butler D, Hwang J, Estick C, Nishiyama A, Kwon R, Colon A, and Charalambides A. Lysosomal modulation ameliorates Alzheimer-type pathology: Evidence of protective cleavage of Aβ42 by modulated cathepsins. FASEB J 23:938.10

(2009).

Bahr BA, Butler D, and Hwang J. Lysosomal modulation reduces Aβ accumulation and promotes synaptic integrity and functional recovery in APPSwInd and APPswe/PS1E9 mice. Alzheimer's and Dementia 4, T486 (Alzheimer’s Association Internatl.Conf. on Alzheimer's Disease) (2008).

Bahr BA, Hwang J, Kwon R, Peterson B, Colon A, Nikas SP, Zhao J, Wood JT, Butler D, Makriyannis A, and Karanian DA. Neuroprotective enhancement of endogenous cannabinoid responses by selective FAAH inhibitor and safety evaluation. Northeastern University’s Center for Drug Discovery Meeting: Medications Development for Drugs of Abuse (2008). Karanian DA, Butler D, Makriyannis A, Bahr BA. Reversible FAAH inhibitor exhibits efficient bioavailability while enhancing neuroprotective endocannabinoid responses. ASPET 2006, San Francisco References for David Butler

*Ben A. Bahr, Ph.D.

William C. Friday Chair and Professor of Molecular Biology & Biochemistry Biotechnology Research and Training Center

115 Livermore Drive University of North Carolina

Pembroke, North Carolina 28372-1510 U.S.A.

office: 910-***-**** ad29kf@r.postjobfree.com

**Jacob P. Harney, Ph.D.

Dean, School of Mathematics and Sciences

Professor of Biology

Reinhardt University

7300 Reinhardt Circle

Waleska, GA 30183-2981

860-***-**** ad29kf@r.postjobfree.com

Jose Manautou, PhD

Dept. Head of Pharmaceutical Sciences and

Professor of Toxicology

School of Pharmacy

University of Connecticut

69 North Eagleville Road Unit 3092

Storrs, CT 06269-3092

860-***-**** ad29kf@r.postjobfree.com

Spiro Pavlopoulos, PhD

Deputy Director, Center for Drug Discovery

Northeastern University

360 Huntington Ave; 116 Mugar Hall

Boston, MA 02115

617-***-**** ad29kf@r.postjobfree.com

J. Larry Renfro, PhD Professor and Head Department of Physiology and Neurobiology University of Connecticut, U3156

75 N. Eagleville Rd. Storrs, CT 06269

Phone: 860-***-****/3285 Fax: 860-***-****

E-mail: ad29kf@r.postjobfree.com

*Doctoral Advisor

**Former department head and Masters Advisor

Contact this candidate